Scandion Oncology

Overcoming cancer drug resistance

Navbar
  • Research & Development
    • Pipeline
    • Clinical Development
    • Science
      • Cancer drug resistance
      • Technology Platform
      • SCO-101
  • News & Press
    • Press releases
  • Investors
    • Share information
    • Financial calendar
    • Financial Reports
      • Annual reports
      • Interim reports
    • Presentations
    • Business development
    • Analyst Coverage
    • Prospectuses
      • Subscription warrants
      • Rights Issue 2024
      • Rights Issue 2022
      • Rights Issue 2020
      • Rights Issue 2019
      • Subscription Warrant (SCOL TO 1)
      • IPO 2018
    • Corporate governance
    • General meetings
Skip to content

Press releases

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
18 December 2020 Letter from the CEO: Great progress in 2020 – we are ready for 2021! Download Presentation Webcast Workbook
18 December 2020 Scandion Oncology tackles antioestrogen resistance Download Presentation Webcast Workbook
18 December 2020 Dansk lægemiddel ser ud til at bekæmpe resistens på tværs af kræftsygdomme Download Presentation Webcast Workbook
16 December 2020Regulatory Scandion Oncology A/S – Flagging message Download Presentation Webcast Workbook
15 December 2020Regulatory Scandion Oncology: Supplement to previously published press release regarding the outcome of Scandion Oncology’s rights issue Download Presentation Webcast Workbook
15 December 2020Regulatory SCANDION ONCOLOGY ANNOUNCES OUTCOME IN THE RIGHTS ISSUE Download Presentation Webcast Workbook
24 November 2020Regulatory Scandion Oncology publishes prospectus relating to the rights issue and announces the intention of changing listing venue to Nasdaq First North Growth Market Sweden Download Presentation Webcast Workbook
20 November 2020 +200 attendees joined our webcast today Download Presentation Webcast Workbook
19 November 2020 Invitation to Scandion Oncology A/S live webcast on 20 November 2020 Download Presentation Webcast Workbook
19 November 2020Regulatory Scandion Oncology – Interim Report Q3 2020 Download Presentation Webcast Workbook
19 November 2020 CEO Bo Rode Hansen interviewed by MedWatch about rights issue Download Presentation Webcast Workbook
17 November 2020Regulatory Correction of previously published press release regarding Scandion Oncology’s rights issue (trading in BTAs) Download Presentation Webcast Workbook
  1. Frontpage

About us

Research & Development

  • Research & Development
  • Pipeline
  • Clinical Development
  • Science

News & Press

  • Press releases
  • Other news
  • Image library items
  • Video library items

Investors

  • Investors
  • Share information
  • Financial Reports
  • Presentations
  • Analyst Coverage
  • Prospectuses
  • Corporate governance
  • Events

Scandion Oncology - The Cancer Drug Resistance Company

Our vision is to overcome cancer drug resistance in order to improve lives for cancer patients and their families

© Copyright 2022 - Scandion Oncology A/S | We use cookies to improve our services | Disclaimer: Market data could be delayed. Delivered by Cision.